An insulin hypersecretion phenotype precedes pancreatic β cell failure in MODY3 patient-specific cells

Cell Stem Cell. 2023 Jan 5;30(1):38-51.e8. doi: 10.1016/j.stem.2022.12.001. Epub 2022 Dec 22.

Abstract

MODY3 is a monogenic hereditary form of diabetes caused by mutations in the transcription factor HNF1A. The patients progressively develop hyperglycemia due to perturbed insulin secretion, but the pathogenesis is unknown. Using patient-specific hiPSCs, we recapitulate the insulin secretion sensitivity to the membrane depolarizing agent sulfonylurea commonly observed in MODY3 patients. Unexpectedly, MODY3 patient-specific HNF1A+/R272C β cells hypersecrete insulin both in vitro and in vivo after transplantation into mice. Consistently, we identified a trend of increased birth weight in human HNF1A mutation carriers compared with healthy siblings. Reduced expression of potassium channels, specifically the KATP channel, in MODY3 β cells, increased calcium signaling, and rescue of the insulin hypersecretion phenotype by pharmacological targeting ATP-sensitive potassium channels or low-voltage-activated calcium channels suggest that more efficient membrane depolarization underlies the hypersecretion of insulin in MODY3 β cells. Our findings identify a pathogenic mechanism leading to β cell failure in MODY3.

Keywords: HNF1A; HNF4A; K(ATP) channel; MODY3; calcium signaling; congenital hyperinsulinemia; disease modeling; membrane potential; pancreatic β cell; patient-specific hiPSCs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2* / genetics
  • Humans
  • Insulin / metabolism
  • Insulin-Secreting Cells* / metabolism
  • Mice
  • Phenotype

Substances

  • Insulin

Supplementary concepts

  • Maturity-Onset Diabetes of the Young, Type 3